ACE2 and COVID-19: An increase in the expression of the ACE2 on the alveolar cells of the lungs of smokers and a consequent increase in mucus secretion by goblet cells has been shown in human and animal models; this can further explain the worse clinical condition of the cancer patients affected by COVID-19 with more aggressive acute respiratory syndrome (Vaduganathan et al., 2020[72]).